Pemetrexed
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Feb 1, 2005 → Mar 1, 2009
NCT ID
NCT00216099About Pemetrexed
Pemetrexed is a phase 2 stage product being developed by Eli Lilly for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00216099. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035061 | Phase 2 | Completed |
| NCT03955042 | Phase 1 | Completed |
| NCT01473563 | Phase 2 | Completed |
| NCT00916630 | Phase 1 | Completed |
| NCT00732303 | Phase 2 | Terminated |
| NCT00864513 | Phase 2 | Terminated |
| NCT00520936 | Phase 2 | Completed |
| NCT00523419 | Phase 2 | Completed |
| NCT00540241 | Pre-clinical | Completed |
| NCT00497770 | Pre-clinical | Completed |
| NCT00316225 | Phase 2 | Completed |
| NCT00380718 | Approved | Completed |
| NCT00377520 | Phase 2 | Completed |
| NCT00190918 | Phase 2 | Completed |
| NCT00330915 | Phase 2 | Completed |
| NCT00109096 | Phase 2 | Completed |
| NCT00106002 | Phase 2 | Completed |
| NCT00216099 | Phase 2 | Completed |
| NCT00190983 | Phase 2 | Completed |
| NCT00216216 | Phase 2 | Terminated |
Competing Products
20 competing products in Prostate Cancer